| アブストラクト | BACKGROUND: Durvalumab consolidation therapy after chemoradiotherapy (CRT) for locally advanced non-small cell lung cancer (NSCLC) is an established standard of care. However, real-world data from claims databases, which capture a broad clinical landscape, are lacking in Asia. This study aimed to characterize real-world treatment patterns and clinical outcomes using a nationwide claims database in Japan. PATIENTS AND METHODS: Patients who received durvalumab after definitive CRT for NSCLC between 2018 and 2024 were identified from the DeSC database. Overall survival (OS) was estimated using the Kaplan-Meier method. Radiation pneumonitis requiring steroid treatment was estimated using the cumulative incidence function with death as a competing risk. RESULTS: A total of 1439 patients were identified, and the median age was 73.6 years. The median durvalumab treatment duration was 5.3 months, and treatment completion rates (>/= 10 and >/= 11 months) were 32.2% and 26.3%, respectively. The median OS was 48.4 months (95% CI, 42.1-57.4 months). The 12-month cumulative incidence of pneumonitis requiring steroid treatment was 19.4% (95% CI, 17.3-21.6%). In multivariable analysis, increasing age, shorter CRT-to-durvalumab interval, pre-existing pneumonitis diagnosis, and respiratory motion management fee were associated with increased pneumonitis risk, whereas the use of intensity-modulated radiotherapy was associated with reduced risk. Among 280 patients who developed pneumonitis, durvalumab rechallenge was administered in 37.5%. CONCLUSION: In this nationwide claims database study, we characterized the clinical practice of CRT with durvalumab treatment and the clinical outcomes in Japan. These real-world findings from Asia complement existing evidence and may inform treatment optimization for durvalumab after CRT. |
|---|
| ジャーナル名 | Clinical lung cancer |
|---|
| Pubmed追加日 | 2026/6/19 |
|---|
| 投稿者 | Takeda, Kazuya; Yamamoto, Takaya; Umezawa, Rei; Takahashi, Noriyoshi; Okuda, Shinsaku; Jingu, Keiichi |
|---|
| 組織名 | Department of Radiation Oncology, Tohoku University Graduate School of Medicine,;Sendai, Miyagi, Japan; Department of Radiation Oncology, South Miyagi Medical;Center, Shibata, Miyagi, Japan. Electronic address:;kazuya.takeda.a8@tohoku.ac.jp.;Sendai, Miyagi, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42314499/ |
|---|
